Developer docs
API playgroundTry for free, no card

Search company profiles

Curebase

Full company profile

uuid0000hqn

Namestring
Curebase
Legal namestring
Curebase, Inc.
Websiteurl
curebase.ai
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Curebase is a privately held clinical trial technology company founded in 2017 and headquartered in San Francisco. It sells an AI-native, cloud-native eClinical platform covering the full trial lifecycle—ePRO/eCOA, eConsent, Electronic Data Capture (EDC), patient recruitment, and participant engagement—built on a single structured database with one codebase and one data model. The company differentiates through proprietary AI features embedded natively into the platform: eCOA Vigilance uses machine learning on behavioral metadata to predict participant non-compliance before surveys are missed; Hope is a conversational voice AI agent for multilingual patient outreach, scheduling, and in-visit data capture; and Curebase Recruit applies AI to dynamic pre-screening and channel ROI tracking. Sitebase, a wholly-owned sub-brand, distributes free CTMS, eISF, eSource, and a Voice AI Receptionist to research sites, creating a two-sided adoption model where site stickiness drives sponsor demand.

The business operates a sales-led, enterprise go-to-market targeting pharma sponsors, biotechs, contract research organizations (CROs), and MedTech companies, with modular subscription pricing for the paid Curebase eClinical Platform and a freemium tier (Sitebase) for sites. The company cites a roster including Walgreens, Krystal Biotech, Premier Research, CellMax Life, Gilead Sciences (strategic investor from the Series B), and MedTech firms such as Madorra, Praeventix, ROSE Diagnostics, and Nectero Therapeutics. Revenue is generated through multi-year study subscriptions priced by capabilities deployed and study scale; pricing is not publicly disclosed. The platform holds SOC 2 Type II, GDPR, 21 CFR Part 11, and EU-U.S. Data Privacy Framework certifications, supporting global deployments including North America and Europe. The company has raised $57.6M in total venture funding ($15M Series A in 2021, $40M Series B in 2022 led by Industry Ventures with Gilead Sciences), employs 100-200 people, and has expanded its executive bench in 2025-2026 with hires including a CCO, VP Operations & Strategy, VP Engineering & Product, and Head of AI.

Short descriptiontext

Curebase is an AI-native eClinical platform company serving pharma, biotech, CRO, and MedTech sponsors with integrated ePRO/eCOA, eConsent, EDC, recruitment, and engagement tools, plus a free Sitebase tier for research sites.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial software, eClinical platform, decentralized trials, electronic data capture, patient recruitment
Industry4 codes
PRIMARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLACAOAA
Electronic Data Capture (EDC) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLACAOAJ
Site & Investigator Platforms (Site Payments, Feasibility, Activation)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs
NAICS code2 codes
  • Computer Systems Design and Related Services54151
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Prepackaged Software7372
Product category
eClinical Platform / Clinical Trial Technology
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Curebase eClinical Platform (Paid Subscription)
TypeSubscription Recurring
Description

Modular, paid end-to-end eClinical platform subscription for sponsors and CROs. Customers pay for access to ePRO/eCOA, eConsent, EDC, recruitment, participant engagement, and AI capabilities. Pricing is tiered by capabilities deployed and study scale. Fully-loaded quotes include implementation, training, and ongoing support.

curebase.ai
2Sitebase (Free Tier)
TypeFreemium
Description

Free core CTMS, eISF, and eSource technology for research sites. Sitebase is provided at no cost to reduce site-level friction and drive sponsor adoption, acting as a customer acquisition and retention mechanism for the paid sponsor platform.

curebase.ai
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Modular platform with configurable capabilities
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Modular pricing based on which capabilities are deployed (ePRO, eConsent, EDC, Recruitment, Engagement, AI). Pricing scales with study size and number of modules. Quotes include implementation, training, and ongoing support. Contact for quote — not publicly listed.

curebase.ai
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Sitebase
Description

Free eClinical suite built specifically for research sites. Sitebase gives sites access to core eClinical tools including CTMS, eISF, and eSource at no cost, reducing administrative burden on site staff and improving data quality.

curebase.ai
Core offering1 text field

Curebase provides a paid, end-to-end AI-native eClinical platform that helps clinical trial sponsors, CROs, biotechs, and MedTech companies launch studies faster, capture higher-quality data, and improve participant engagement across the full trial lifecycle (ePRO/eCOA, eConsent, EDC, recruitment, and engagement). The company also offers Sitebase, a free eClinical suite providing CTMS, eISF, and eSource technology to research sites to reduce administrative burden and drive bottom-up platform adoption.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Studies can launch in 6 weeks with 95% of patients submitting all core endpoint data
+5 more records
Product overview1 text field

Curebase offers a unified, AI-native eClinical platform that combines ePRO/eCOA, eConsent, Electronic Data Capture (EDC), Patient Recruitment (Curebase Recruit), Patient Engagement, Site Management (Sitebase), and AI capabilities (Hope voice agent, eCOA Vigilance) in a single structured system. The platform is designed for sponsors, CROs, biotechs, MedTech companies, and research sites. Sitebase provides free CTMS, eISF, and eSource technology for research sites, while the paid Curebase eClinical Platform covers the full trial lifecycle for sponsors and CROs.

Product and service2 records
1Curebase eClinical Platform
CategoryeClinical Platform
Description

Paid end-to-end AI-native eClinical platform for sponsors, CROs, biotechs, and MedTech companies that integrates ePRO/eCOA, eConsent, EDC, recruitment, engagement, and AI capabilities in a single structured system. Designed to help trial teams launch studies faster, capture cleaner data, and improve participant engagement across the full trial lifecycle.

2Sitebase
CategorySite Technology (Free eClinical Suite)
Description

Free eClinical suite built specifically for research sites, providing access to core eClinical tools including CTMS, Investigator Site Files (eISF), and eSource at no cost. Reduces administrative burden on site staff, improves data quality at the point of collection, and removes financial barriers to activating community research locations.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Industry-leading eClinical platform offering EDC, eCOA, eConsent, CTMS, and RTSM as part of the broader Dassault Systèmes life sciences portfolio. Curebase's most direct large-enterprise competitor in the same buyer set.

TypeBroad incumbent
Description

Enterprise cloud software provider for life sciences, including Veeva Vault CTMS, Vault EDC, ePRO, and eConsent. Competes with Curebase in large pharma for global trial platform standardization.

TypeDirect peer
Description

Decentralized clinical trial platform offering eCOA, eConsent, telehealth, and patient engagement for sponsors and CROs. Direct competitor in the DCT and modular eClinical space targeted at the same biotech/pharma buyer segments.

TypeDirect peer
Description

Decentralized clinical trial technology and operating company focused on bringing trials directly to patients' homes. Overlaps with Curebase's decentralized trial capabilities and sponsor-centric GTM.

TypeDirect peer
Description

Cloud-based EDC and eClinical platform with strong adoption among emerging biotech and academic sponsors. Competes head-to-head with Curebase in the emerging biotech and modular-pricing segments.

TypeDirect peer
Description

Provides eCOA, eConsent, patient engagement, and clinical supply chain solutions for clinical trials. Direct overlap with Curebase's ePRO/eCOA, eConsent, and engagement modules across pharma and biotech.

TypeDirect peer
Description

Decentralized clinical trial platform supporting eCOA, eConsent, virtual visits, and patient engagement. Competes with Curebase in DCT deployments for mid-market biotech and pharma.

TypeBroad incumbent
Description

Broad clinical trial technology and endpoints company offering EDC, eCOA, imaging, and cardiac safety solutions. Larger incumbent competing for enterprise eClinical RFPs alongside Curebase.

9Oracle Health Sciences (Clinical One)
TypeBroad incumbent
Description

Oracle's unified eClinical platform (formerly goBalto/Clinical One) covering EDC, RTSM, ePRO, and CTMS. Enterprise-scale incumbent competing for global pharma standardization deals.

TypeBroad incumbent
Description

Largest CRO with a broad eClinical technology stack and DCT capabilities through the IQVIA Decentralized Trials platform. Competes with Curebase both as a CRO partner and as a technology provider to sponsors.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Curebase

eClinical Platform / Clinical Trial Technologycurebase.ai

Curebase is an AI-native eClinical platform company serving pharma, biotech, CRO, and MedTech sponsors with integrated ePRO/eCOA, eConsent, EDC, recruitment, and engagement tools, plus a free Sitebase tier for research sites.

What Curebase does

Curebase is a privately held clinical trial technology company founded in 2017 and headquartered in San Francisco. It sells an AI-native, cloud-native eClinical platform covering the full trial lifecycle—ePRO/eCOA, eConsent, Electronic Data Capture (EDC), patient recruitment, and participant engagement—built on a single structured database with one codebase and one data model. The company differentiates through proprietary AI features embedded natively into the platform: eCOA Vigilance uses machine learning on behavioral metadata to predict participant non-compliance before surveys are missed; Hope is a conversational voice AI agent for multilingual patient outreach, scheduling, and in-visit data capture; and Curebase Recruit applies AI to dynamic pre-screening and channel ROI tracking. Sitebase, a wholly-owned sub-brand, distributes free CTMS, eISF, eSource, and a Voice AI Receptionist to research sites, creating a two-sided adoption model where site stickiness drives sponsor demand.

The business operates a sales-led, enterprise go-to-market targeting pharma sponsors, biotechs, contract research organizations (CROs), and MedTech companies, with modular subscription pricing for the paid Curebase eClinical Platform and a freemium tier (Sitebase) for sites. The company cites a roster including Walgreens, Krystal Biotech, Premier Research, CellMax Life, Gilead Sciences (strategic investor from the Series B), and MedTech firms such as Madorra, Praeventix, ROSE Diagnostics, and Nectero Therapeutics. Revenue is generated through multi-year study subscriptions priced by capabilities deployed and study scale; pricing is not publicly disclosed. The platform holds SOC 2 Type II, GDPR, 21 CFR Part 11, and EU-U.S. Data Privacy Framework certifications, supporting global deployments including North America and Europe. The company has raised $57.6M in total venture funding ($15M Series A in 2021, $40M Series B in 2022 led by Industry Ventures with Gilead Sciences), employs 100-200 people, and has expanded its executive bench in 2025-2026 with hires including a CCO, VP Operations & Strategy, VP Engineering & Product, and Head of AI.

Curebase firmographics

Firmographics
Name
Curebase
Legal name
Curebase, Inc.
Website
https://curebase.ai
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Short description
Curebase is an AI-native eClinical platform company serving pharma, biotech, CRO, and MedTech sponsors with integrated ePRO/eCOA, eConsent, EDC, recruitment, and engagement tools, plus a free Sitebase tier for research sites.
Ownership category
akta.pro rank

Curebase industry classification

Industry
Product category
eClinical Platform / Clinical Trial Technology
NAICS
Computer Systems Design and Related Services (54151), Scientific Research and Development Services (5417)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLACAOAA
Electronic Data Capture (EDC) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLACAOAJ
Site & Investigator Platforms (Site Payments, Feasibility, Activation)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs

Keywords

  • Clinical trial software
  • EClinical platform
  • Decentralized trials
  • Electronic data capture
  • Patient recruitment

Where Curebase is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Curebase business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Curebase eClinical Platform (Paid Subscription): Modular, paid end-to-end eClinical platform subscription for sponsors and CROs. Customers pay for access to ePRO/eCOA, eConsent, EDC, recruitment, participant engagement, and AI capabilities. Pricing is tiered by capabilities deployed and study scale. Fully-loaded quotes include implementation, training, and ongoing support.
  2. Sitebase (Free Tier): Free core CTMS, eISF, and eSource technology for research sites. Sitebase is provided at no cost to reduce site-level friction and drive sponsor adoption, acting as a customer acquisition and retention mechanism for the paid sponsor platform.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractModular platform with configurable capabilities

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Curebase product offering

Product offering

Core offering

Curebase provides a paid, end-to-end AI-native eClinical platform that helps clinical trial sponsors, CROs, biotechs, and MedTech companies launch studies faster, capture higher-quality data, and improve participant engagement across the full trial lifecycle (ePRO/eCOA, eConsent, EDC, recruitment, and engagement). The company also offers Sitebase, a free eClinical suite providing CTMS, eISF, and eSource technology to research sites to reduce administrative burden and drive bottom-up platform adoption.

Product overview

Curebase offers a unified, AI-native eClinical platform that combines ePRO/eCOA, eConsent, Electronic Data Capture (EDC), Patient Recruitment (Curebase Recruit), Patient Engagement, Site Management (Sitebase), and AI capabilities (Hope voice agent, eCOA Vigilance) in a single structured system. The platform is designed for sponsors, CROs, biotechs, MedTech companies, and research sites. Sitebase provides free CTMS, eISF, and eSource technology for research sites, while the paid Curebase eClinical Platform covers the full trial lifecycle for sponsors and CROs.

Differentiator

Problem solved

Functional benefit

Brands

  • Sitebase: Free eClinical suite built specifically for research sites. Sitebase gives sites access to core eClinical tools including CTMS, eISF, and eSource at no cost, reducing administrative burden on site staff and improving data quality.

Products and services

  • Curebase eClinical Platform Paid end-to-end AI-native eClinical platform for sponsors, CROs, biotechs, and MedTech companies that integrates ePRO/eCOA, eConsent, EDC, recruitment, engagement, and AI capabilities in a single structured system. Designed to help trial teams launch studies faster, capture cleaner data, and improve participant engagement across the full trial lifecycle.
  • Sitebase Free eClinical suite built specifically for research sites, providing access to core eClinical tools including CTMS, Investigator Site Files (eISF), and eSource at no cost. Reduces administrative burden on site staff, improves data quality at the point of collection, and removes financial barriers to activating community research locations.

Quantifiable outcome

  • Studies can launch in 6 weeks with 95% of patients submitting all core endpoint data
  • +5 more outcomes

Companies that use Curebase

Customer profile

Named customers11 records

Segments6 records

Ideal customer profiles5 records

Curebase technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

Curebase partnerships and signals

Strategic signal

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Curebase competitors and assessment

Company assessment

Broad incumbents

  • Medidata (Dassault Systèmes): Industry-leading eClinical platform offering EDC, eCOA, eConsent, CTMS, and RTSM as part of the broader Dassault Systèmes life sciences portfolio. Curebase's most direct large-enterprise competitor in the same buyer set.
  • Veeva Systems: Enterprise cloud software provider for life sciences, including Veeva Vault CTMS, Vault EDC, ePRO, and eConsent. Competes with Curebase in large pharma for global trial platform standardization.
  • Clario: Broad clinical trial technology and endpoints company offering EDC, eCOA, imaging, and cardiac safety solutions. Larger incumbent competing for enterprise eClinical RFPs alongside Curebase.
  • Oracle Health Sciences (Clinical One): Oracle's unified eClinical platform (formerly goBalto/Clinical One) covering EDC, RTSM, ePRO, and CTMS. Enterprise-scale incumbent competing for global pharma standardization deals.
  • IQVIA: Largest CRO with a broad eClinical technology stack and DCT capabilities through the IQVIA Decentralized Trials platform. Competes with Curebase both as a CRO partner and as a technology provider to sponsors.

Direct peers

  • Medable: Decentralized clinical trial platform offering eCOA, eConsent, telehealth, and patient engagement for sponsors and CROs. Direct competitor in the DCT and modular eClinical space targeted at the same biotech/pharma buyer segments.
  • Science 37: Decentralized clinical trial technology and operating company focused on bringing trials directly to patients' homes. Overlaps with Curebase's decentralized trial capabilities and sponsor-centric GTM.
  • Castor: Cloud-based EDC and eClinical platform with strong adoption among emerging biotech and academic sponsors. Competes head-to-head with Curebase in the emerging biotech and modular-pricing segments.
  • Signant Health: Provides eCOA, eConsent, patient engagement, and clinical supply chain solutions for clinical trials. Direct overlap with Curebase's ePRO/eCOA, eConsent, and engagement modules across pharma and biotech.
  • THREAD Research: Decentralized clinical trial platform supporting eCOA, eConsent, virtual visits, and patient engagement. Competes with Curebase in DCT deployments for mid-market biotech and pharma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Curebase social profiles

Digital presence

Curebase compliance and trust

Trust signal

Compliance7 records

Curebase financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Curebase leadership team

Management profile

Number of profiles

Profiles10 records

Curebase subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Curebase funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Curebase M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curebase

What does Curebase do?

Curebase provides a paid, end-to-end AI-native eClinical platform that helps clinical trial sponsors, CROs, biotechs, and MedTech companies launch studies faster, capture higher-quality data, and improve participant engagement across the full trial lifecycle (ePRO/eCOA, eConsent, EDC, recruitment, and engagement). The company also offers Sitebase, a free eClinical suite providing CTMS, eISF, and eSource technology to research sites to reduce administrative burden and drive bottom-up platform adoption.

Is Curebase a public or private company?

Curebase is a private company. It is classified as venture growth investor backed and is currently operating.

When was Curebase founded?

Curebase was founded in 2017. It employs 51 to 100 people.

Where is Curebase based?

Curebase is headquartered in San Francisco, United States, in the North America region.

How does Curebase make money?

Two revenue lines are on record. Curebase eClinical Platform (Paid Subscription) is the primary driver. The others are sitebase (Free Tier).

Who are Curebase's main competitors?

Broad incumbents on record are Medidata (Dassault Systèmes), Veeva Systems, Clario, Oracle Health Sciences (Clinical One) and IQVIA. Direct peers are Medable, Science 37, Castor, Signant Health and THREAD Research.

Does Curebase have an API?

No public API is recorded for Curebase.

What industry is Curebase in?

Curebase's product category is eClinical Platform / Clinical Trial Technology. Its primary akta.pro industry code is HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF), with a secondary code of HLACAOAA, Electronic Data Capture (EDC) Platforms. Its NAICS code is 54151 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireAI Disruption to Transform $8.5 Billion Decentralized Clinical Trials Market as Investment Activity SurgesBCC Research has released an analysis examining how artificial intelligence is transforming the $8.5 billion decentralized clinical trials (DCT) market, addressing critical inefficiencies that have historically caused delays and failed studies. Leading DCT platforms have raised over $650 million in recent funding rounds, with Medable securing $506.6 million total including a $304 million Series D in 2021, and Lindus Health raising $55 million in Series B in 2025, while top pharmaceutical companies report threefold acceleration in patient recruitment and 40% reduction in screen-failure rates using AI-powered systems. Key players including Medable, Science 37, Lindus Health, Curebase, Castor, Deep 6 AI, Veeva Systems, IQVIA, and Medidata are establishing dominant positions through strategic AI integration as the sector benefits from regulatory tailwinds favoring remote trial models.CurebaseWhat is ePRO for Clinical Trials? A Comprehensive GuideThis article provides a comprehensive guide to electronic Patient-Reported Outcomes (ePRO), defining it as a digital method for collecting health data directly from clinical trial participants. It outlines the key components, benefits such as enhanced data quality and operational efficiency, and various implementation strategies like BYOD or provisioned devices. The text also highlights Curebase as a unified platform provider that integrates ePRO with other study functions.outsourcing-pharma.comFive decentralized clinical trial organizations raising big VC cashFive decentralized clinical trial organizations—Curavit, Curebase, Florence, Lightship, and Reify—raised significant venture capital in recent years. The DCT market was valued at $7.7 billion in 2022 and is projected to grow 7.6% annually through 2033. The companies are using funds to expand platforms and partnerships.outsourcing-pharma.comFive decentralized clinical trial organizations raising big VC cashFive decentralized clinical trial organizations—Curavit, Curebase, Florence, Lightship, and Reify—raised significant venture capital in recent years. The DCT market was valued at $7.7 billion in 2022 and is projected to grow 7.6% annually through 2033. The companies are using funds to expand their platforms and operations.PR NewswireCurebase Selected Among Y Combinator's Top Private Companies of 2023Curebase, a decentralized clinical trials platform company, has been named among Y Combinator's 2023 Top Private Companies, placing in the top 6% of all companies on the list. The recognition validates Curebase's position as a leader in the DCT market, with the company having completed a successful 2022 that included a $40 million Series B funding round featuring a strategic investment from Gilead Sciences. The company also reported launching 21 new studies, enrolling 5,824 patients, enabling 10,643 site visits, and reaching 4,111 zip codes for patient prescreening.PR NewswireCurebase Launches All-in-One Software and Trial Execution Package to Help Digital Therapeutics Companies Accelerate Clinical TrialsCurebase launched an integrated software and services package for digital therapeutics trials, combining a decentralized clinical trial platform with site and execution services. The company has completed 17 DTx studies, enrolled over 3,500 patients, and prescreened tens of thousands. The offering aims to streamline vendor selection and trial execution for DTx sponsors.PR NewswireCUREBASE MEDIA ALERTCurebase issued a media alert announcing that Jane Myles, the company's vice president of clinical trial innovation, will participate as a panelist in a White House OSTP/ONC listening session on optimizing data capture for clinical trials on January 11, 2023. The webinar aims to address the need for a coordinated clinical trials enterprise capable of responding to emerging viral threats and evaluating vaccines and therapeutics across diverse participants.PR NewswireCurebase Celebrates Year of Growth, Organizational MaturityCurebase, a San Francisco-based decentralized clinical trials platform company, announced successful 2022 results including launching 21 new studies, enrolling 5,824 patients across 4,111 zip codes, and releasing its Universal Mobile App. The company raised $40 million in Series B funding in May, with strategic investment from Gilead Sciences to deepen their partnership in DCT implementation. Curebase celebrated its fifth anniversary in November and plans to focus on diagnostics and digital therapeutics studies in 2023.PR NewswireCurebase Releases Diagnostic Offering that Delivers First All-Inclusive Package of Software and Services Needed to Fully Execute Diagnostic StudiesCurebase announced the launch of an integrated software and services package designed to accelerate the execution of diagnostic clinical trials by reducing start-up times and enrollment costs. The offering leverages decentralized clinical trial technology and existing infrastructure to help sponsors quickly launch studies, with reported results showing significantly higher patient enrollment rates compared to traditional methods.